Wall Street analyst price targets, ratings consensus & upside potential · Updated Feb 28, 2026
Last 12 months price action with 12-month analyst target path
As of February 28, 2026, Bristol-Myers Squibb Company (BMY) has a Wall Street consensus price target of $62.27, based on estimates from 41 covering analysts. With the stock currently trading at $62.37, this represents a potential downside of -0.2%. The company has a market capitalization of $127.01B.
Analyst price targets range from a low of $40.00 to a high of $75.00, representing a 56% spread in expectations. The median target of $60.00 aligns closely with the consensus average. The wide target spread reflects significant disagreement on fair value.
The current analyst consensus rating is Hold, with 19 analysts rating the stock as a Buy or Strong Buy,20 rating it Hold, and 2 rating it Sell or Strong Sell. The mixed ratings reflect uncertainty about near-term direction.
From a valuation perspective, BMY trades at a trailing P/E of -14.1x and forward P/E of 10.0x. Analysts expect EPS to grow +110.3% over the next year.
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how BMY stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonWall Street's consensus price target for BMY is $62.27, -0.2% from its current price of $62.37. The below-market target from 41 analysts suggests limited near-term appreciation.
BMY has a consensus rating of "Hold" based on 41 Wall Street analysts. The rating breakdown is mixed, with 20 Hold ratings making up the largest segment. The consensus 12-month price target of $62.27 implies -0.2% downside from current levels.
With a forward P/E of 10.0087x, BMY trades at a relatively low valuation. The consensus target of $62.27 implies -0.2% move, suggesting the market may be pricing in risks.
The most bullish Wall Street analyst has a price target of $75 for BMY, while the most conservative target is $40. The consensus of $62.27 represents the median expectation. These targets typically reflect 12-month expectations.
BMY is heavily covered by Wall Street, with 41 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 19 have Buy ratings, 20 recommend Hold, and 2 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month BMY stock forecast based on 41 Wall Street analysts shows a consensus price target of $62.27, with estimates ranging from $40 (bear case) to $75 (bull case). The median consensus rating is "Hold".
BMY trades at a forward P/E ratio of 10.0x based on next-twelve-months earnings estimates. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Analysts are cautious on BMY, with 2 Sell ratings and a price target of $62.27 (-0.2% from current price). The "Hold" consensus suggests careful evaluation before buying. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
BMY analyst price targets range from $40 to $75, a 56% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $62.27 consensus represents the middle ground.